[{"address1": "10240 Bubb Road", "city": "Cupertino", "state": "CA", "zip": "95014-4166", "country": "United States", "phone": "408 777 1417", "fax": "408 777 3577", "website": "https://www.durect.com", "industry": "Drug Manufacturers\u2014Specialty & Generic", "sector": "Healthcare", "longBusinessSummary": "DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.", "fullTimeEmployees": 48, "companyOfficers": [{"maxAge": 1, "name": "Dr. James E. Brown D.V.M.", "age": 66, "title": "Co-Founder, CEO, President & Director", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 633464, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Timothy M. Papp M.B.A.", "age": 47, "title": "CFO & Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 427616, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Norman L. Sussman M.D.", "age": 70, "title": "Chief Medical Officer", "yearBorn": 1953, "fiscalYear": 2023, "totalPay": 471706, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Judy R. Joice", "age": 66, "title": "Senior Vice President of Operations & Corporate Quality Assurance", "yearBorn": 1957, "fiscalYear": 2023, "totalPay": 451816, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. WeiQi  Lin M.D., Ph.D.", "title": "Executive VP of Research & Development and Principal Scientist", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Keith L. Lui M.B.A.", "title": "Senior Vice President of Business Development, Commercial & Medical Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jian  Li M.B.A.", "age": 53, "title": "Senior VP of Finance, Corporate Controller & Secretary", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 297081, "exercisedValue": 16406, "unexercisedValue": 182381}, {"maxAge": 1, "name": "Dr. Su Il Yum Ph.D.", "age": 84, "title": "Executive Officer", "yearBorn": 1939, "fiscalYear": 2023, "totalPay": 331744, "exercisedValue": 62436, "unexercisedValue": 162964}], "auditRisk": 9, "boardRisk": 2, "compensationRisk": 5, "shareHolderRightsRisk": 7, "overallRisk": 6, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.59, "open": 1.6, "dayLow": 1.55, "dayHigh": 1.655, "regularMarketPreviousClose": 1.59, "regularMarketOpen": 1.6, "regularMarketDayLow": 1.55, "regularMarketDayHigh": 1.655, "beta": 1.139, "forwardPE": -1.2272726, "volume": 68752, "regularMarketVolume": 68752, "averageVolume": 83988, "averageVolume10days": 50970, "averageDailyVolume10Day": 50970, "bid": 1.59, "ask": 1.66, "bidSize": 100, "askSize": 100, "marketCap": 50283828, "fiftyTwoWeekLow": 0.47, "fiftyTwoWeekHigh": 3.14, "priceToSalesTrailing12Months": 5.978341, "fiftyDayAverage": 1.4188, "twoHundredDayAverage": 1.06645, "currency": "USD", "enterpriseValue": 49770616, "profitMargins": -1.87837, "floatShares": 29722380, "sharesOutstanding": 31039400, "sharesShort": 1224892, "sharesShortPriorMonth": 1224111, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0395, "heldPercentInsiders": 0.0579, "heldPercentInstitutions": 0.24418, "shortRatio": 19.21, "shortPercentOfFloat": 0.0398, "bookValue": 0.162, "priceToBook": 10.0, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -15799000, "trailingEps": -0.61, "forwardEps": -1.32, "pegRatio": -0.12, "enterpriseToRevenue": 5.917, "enterpriseToEbitda": -1.996, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "DRRX", "underlyingSymbol": "DRRX", "shortName": "DURECT Corporation", "longName": "DURECT Corporation", "firstTradeDateEpochUtc": 970147800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e77ce79d-8bdf-33c2-8d1b-fd9ac415ef17", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.62, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 15646000, "totalCashPerShare": 0.504, "ebitda": -24930000, "totalDebt": 16064000, "quickRatio": 0.76, "currentRatio": 0.91, "totalRevenue": 8411000, "debtToEquity": 318.92, "revenuePerShare": 0.284, "returnOnAssets": -0.39695, "returnOnEquity": -2.9987702, "freeCashflow": -24426376, "operatingCashflow": -26240000, "revenueGrowth": 0.043, "grossMargins": -1.47212, "ebitdaMargins": -2.9639802, "operatingMargins": -1.5679401, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]